Covishield & covaxin: a deep dive into India's covid-19 vaccine saga & recent safety updates

India’s battle against the COVID-19 pandemic was spearheaded by a monumental vaccination drive, primarily powered by two vaccines: Covishield and Covaxin. While the campaign was a public health triumph, recent developments have brought the conversation around vaccine side effects back into focus, making it a critical topic for UPSC aspirants.

In a significant 2024 development, pharmaceutical giant AstraZeneca admitted in UK court documents that its vaccine, sold as Covishield in India, can in very rare cases lead to a side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). This condition involves blood clots and a low platelet count. While health authorities, including the WHO, have maintained that the vaccine’s benefits far outweigh this extremely rare risk, this admission provides a new analytical layer to the vaccine discourse.

Fun Fact: The technology behind Covishield uses a modified chimpanzee adenovirus (ChAdOx1) as a “vector” to carry the genetic instructions for the SARS-CoV-2 spike protein into the body. This virus is harmless to humans and cannot cause disease.

Comparing India’s Frontline Vaccines

Covishield and Covaxin are based on entirely different technological platforms, which influences their mechanism, efficacy, and side effect profile.

Fun Fact: Covaxin was India’s first indigenously developed COVID-19 vaccine, a landmark achievement for the Atmanirbhar Bharat (self-reliant India) mission in the pharmaceutical space.

To remember the vaccine types, use the following mnemonic:

Mnemonic: VICK

• Viral Vector Is Covishield’s Kind. (This helps associate the ‘V’ in Viral Vector with Covishield)

Critical Policy Appraisal

India’s vaccination strategy was a complex exercise in governance, balancing public health, logistics, and international diplomacy.

Fun Fact: India administered over 2.2 billion COVID-19 vaccine doses, one of the largest and fastest vaccination campaigns in human history.

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis

The legal and administrative framework for India’s pandemic response, including the vaccine rollout, was primarily enabled by two key pieces of legislation:

1. The Epidemic Diseases Act, 1897: A colonial-era law that grants special powers to central and state governments to implement measures to prevent the spread of dangerous epidemic diseases.
2. The Drugs and Cosmetics Act, 1940: This act regulates the import, manufacture, and distribution of pharmaceuticals in India, ensuring their safety and quality. Emergency Use Authorization (EUA) for vaccines was granted under the provisions of this act.

UPSC Integration: Connecting the Dots

• GS Paper 2 (Polity & Governance, International Relations): The topic connects to federalism (Centre-State coordination on health, a state subject), public health governance, and health diplomacy (Vaccine Maitri initiative).
• GS Paper 3 (Economy, Science & Technology): It links directly to the pharmaceutical industry, issues of Intellectual Property Rights (IPR) like the TRIPS waiver debate, and advancements in biotechnology.

Expert Analysis: Future Impact

The COVID-19 vaccination drive has permanently altered India’s public health landscape. It has stress-tested and revealed both the strengths and weaknesses of the country’s healthcare infrastructure. The long-term impact will be seen in a more robust domestic pharmaceutical R&D ecosystem, a greater focus on genomic surveillance for new variants, and a more assertive role for India in global health governance. The lessons learned in supply chain management and digital health platforms like CoWIN will serve as foundational assets for future national health programs. However, maintaining public trust through transparent communication about rare adverse events remains a key policy challenge for the future.

Prelims Practice Question (MCQ)

Question: With reference to COVID-19 vaccine technologies, which of the following statements is correct? a) Covishield uses an mRNA platform to introduce spike protein into the body. b) Covaxin is a viral vector vaccine that uses a disabled adenovirus. c) Covishield uses a non-replicating viral vector to deliver the gene for the SARS-CoV-2 spike protein. d) Covaxin is a subunit vaccine containing purified spike proteins.

Answer and Explanation: c) Covishield uses a non-replicating viral vector to deliver the gene for the SARS-CoV-2 spike protein. Explanation: Covishield is based on the Oxford-AstraZeneca vaccine, which employs a chimpanzee adenovirus (a viral vector) modified so it cannot replicate in humans. Covaxin is an inactivated virus vaccine. mRNA technology was used in vaccines like Pfizer-BioNTech and Moderna.

Mains Sample Question

Question (15 Marks): “India’s COVID-19 vaccination strategy was a testament to its pharmaceutical prowess but also a trial by fire for its public health governance. Critically analyze this statement, focusing on the successes of the ‘Vaccine Maitri’ initiative and the challenges posed by vaccine safety concerns and digital inclusion. What are the key lessons for future pandemic preparedness?”

Mind Map Outline (Revision Structure)

• India’s COVID-19 Vaccination: Covishield & Covaxin
  • Core Vaccines
    • Covishield
      • Developer: Serum Institute of India (from AstraZeneca)
      • Technology: Viral Vector (ChAdOx1)
      • Global Role: Key part of COVAX
    • Covaxin
      • Developer: Bharat Biotech & ICMR
      • Technology: Inactivated Virus
      • Significance: India’s first indigenous COVID-19 vaccine
  • Key Developments & Safety Profile
    • AstraZeneca’s 2024 Admission
      • Acknowledgement of link to Thrombosis with Thrombocytopenia Syndrome (TTS)
      • Context: Extremely rare side effect
      • Impact: Renewed debate on vaccine transparency and pharmacovigilance
    • Common vs. Rare Side Effects
      • Common: Fever, fatigue, injection site pain
      • Rare (Covishield): TTS
  • Policy & Governance Dimensions
    • Legal Framework
      • Epidemic Diseases Act, 1897
      • Drugs and Cosmetics Act, 1940
    • Critical Appraisal
      • Challenges: Vaccine hesitancy, digital divide (CoWIN), TTS concerns
      • Successes: ‘Vaccine Maitri’ diplomacy, Atmanirbhar Bharat in pharma, rapid rollout
  • UPSC Analytical Framework
    • Inter-Topic Linkages
      • GS Paper 2: Federalism, Health Governance, International Relations
      • GS Paper 3: Economy (Pharma), Science & Tech (Biotech)
    • Future Outlook
      • Strengthening public health infrastructure
      • Enhancing global health diplomacy
      • Need for robust post-market surveillance